Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Samrat PharmachemBOM:530125 -0.69%69 ROC (Joel Greenblatt) % is 10.43% as of Jun. 2026, which is 51% below its 10-year median of 21.30. GuruFocus rates BOM:530125 with a GF Score™ of 69/100 and a GF Value™ of ₹355.67 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,612 Chemicals companies, Samrat Pharmachem ranks worse than 81.27% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Samrat Pharmachem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 10.43%.
The historical rank and industry rank for Samrat Pharmachem's ROC (Joel Greenblatt) % or its related term are showing as below:
BOM:530125'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3.67 Med: 21.3 Max: 66.63
Current: -1.51
During the past 13 years, Samrat Pharmachem's highest ROC (Joel Greenblatt) % was 66.63%. The lowest was -3.67%. And the median was 21.30%.
BOM:530125's ROC (Joel Greenblatt) % is ranked worse than 81.27% of 1612
companies
in the Chemicals industry
Industry Median: 10.59
vs BOM:530125: -1.51
Samrat Pharmachem's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Samrat Pharmachem ROC (Joel Greenblatt) % Related Terms
Samrat Pharmachem ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Samrat Pharmachem's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530125 vs DOW: ROC (Joel Greenblatt) % Comparison
For the Chemicals subindustry, Samrat Pharmachem's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Samrat Pharmachem ROC (Joel Greenblatt) % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Samrat Pharmachem's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Samrat Pharmachem's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 10.43% mean?
Samrat Pharmachem (BOM:530125) has a ROC (Joel Greenblatt) % of 10.43% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Samrat Pharmachem and its competitors. This is 51% below median its historical median of 21.30. According to the industry distribution chart, Samrat Pharmachem ranks #1310 out of 1612 companies in the Chemicals industry, placing it in the top 81.3%.
Is Samrat Pharmachem's ROC (Joel Greenblatt) % too high?
Samrat Pharmachem's current ROC (Joel Greenblatt) % of 10.43% is 51% below median its 10-year median of 21.30. The Chemicals industry median ROC (Joel Greenblatt) % is 10.59. Samrat Pharmachem's value of 10.43% is 1.5% below this industry median. Based on the distribution chart, Samrat Pharmachem ranks #1310 out of 1612 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Samrat Pharmachem has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's ROC (Joel Greenblatt) % compare to DOW?
According to the Chemicals industry distribution chart, Samrat Pharmachem ranks #1310 out of 1612 companies for ROC (Joel Greenblatt) %. This places Samrat Pharmachem in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 10.59. Samrat Pharmachem's value of 10.43% is 1.5% below this benchmark. While the company's 10-year median is 21.30 vs. the industry median of 10.59, Samrat Pharmachem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Chemicals company?
The median ROC (Joel Greenblatt) % among Chemicals companies is 10.59, based on 1,612 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Samrat Pharmachem's current ROC (Joel Greenblatt) % of 10.43% is 1.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Samrat Pharmachem and its competitors. For the Chemicals industry, the median ROC (Joel Greenblatt) % is 10.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Samrat Pharmachem's current ROC (Joel Greenblatt) % is 10.43%, which is 51% below median its own 10-year median of 21.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Possible Value Trap. The stock's GF Value™ is ₹355.67, compared to a current price of ₹229.90 — trading 35.4% below its estimated fair value. The current ROC (Joel Greenblatt) % is 10.43%, which is 51% below median its 10-year median of 21.30 and 1.5% below the Chemicals industry median of 10.59. Samrat Pharmachem's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current ROC (Joel Greenblatt) % is 10.43% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?
Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued.
The current stock price of ₹229.90 is trading 35.4% below its estimated GF Value™ of ₹355.67.
GuruFocus considers Samrat Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:530125:
ROC (Joel Greenblatt) %: 10.43% (51% below median its 10-year median of 21.30)
GF Value™: ₹355.67 vs. price of ₹229.90 (35.4% below fair value)
Industry Position: 1.5% below the Chemicals median (#1310 of 1612)
No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
69GF Score
Get the complete analysis for BOM:530125
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530125 has been successfully added to your 
